Healixia webinar: ‘Most Favored Nation’ Executive Order: Impact on Belgian Medicines Access?
Have already registered
| Last name | First name | Organization |
|---|---|---|
| Beghin | Emilie | - |
| Cattoir | Céline | Healixia |
| Commers | Kathleen | Pfizer N.V. – S.A. |
| Coppenrath | Marilyn | - |
| Daissormont | Isabelle | Amgen Belgium nv |
| De Cock | Roosmarijn | Axes Health BV |
| De Groote | Katrien | Innosens bv |
| Gesquiere | Ina | AstraZeneca nv/sa |
| Goffart | Benedicte | argenx |
| Hoebus | Marleen | Janssen-Cilag NV |
| Huybrechts | Sofie | Biogen Belgium NV/SA |
| Iven | Julie | AstraZeneca nv/sa |
| Jonckers | Nele | Simmons & Simmons LLP |
| Leroi | Hermine | MSD Europe Belgium SRL |
| Libert | Cédric | GILEAD Sciences Belgium bv |
| Lins | Veronique | Janssen Pharmaceutica NV |
| Marinovic | Ines | Teva Pharma Belgium |
| Martens | Arne | E&A Pharma |
| Minnaert | An-Katrien | Axes Health BV |
| Nauwelaerts | Chana | Sanofi |
| Populaire | Cile | Daiichi Sankyo Belgium |
| Ramboer | Isabelle | Cliniques Universitaires Saint-Luc |
| Sente | Tahnee | S.A. NOVO NORDISK PHARMA N.V. |
| Smitz | Liesbet | - |
| T'Jampens | Davy | Takeda Belgium NV |
| Van den Broeck | Anke | AstraZeneca nv/sa |
| Van Driessche | Luc | ROCHE sa/nv |
| Van Riet | Camille | SGS Belgium nv |
| Vandebrouck | Tom | Vandebrouck Coaching and consulting |
| Vandermeersch | Dieter | Sobi - Swedish Orphan Biovitrum |
| Vandewiele | Frone | Kintiga (AxTalis BV) |
| Vandyck | Glen | GILEAD Sciences Belgium bv |
| Voeten | Sam | Janssen-Cilag NV |
| Volckaert | Mia | Pharmia Consult B.V. |
| Wollaert | Lieve | LIWOMA BV |